JAKARTA - The Food and Drug Supervisory Agency (BPOM) has submitted a certificate of Good Manufacturing Practices (CPOB) for the Red and White Vaccine made by Airlangga University (Unair) and PT Biotis Pharmaceutical Indonesia.

In developing the COVID-19 vaccine, Unair is collaborating with PT Biotis Pharmaceutical Indonesia in developing a vaccine with an inactivated virus platform.

Responding to this information, Member of Commission IX DPR RI Yahya Zaini said the granting of the GMP certificate was carried out because it had fulfilled a number of assessments determined by BPOM. Among them, the design of production facilities, implementation of inspections, assistance, consultation to repairs.

“The Red and White Vaccine developed by Unair is purely the work of the nation's children. Because starting from the development of vaccine seeds, the formulation, production and filling processes are all carried out in Indonesia,” said Yahya Zaini, Thursday, August 19.

The Golkar Party legislator also appreciated Unair's achievement for being the most superior among the six candidates for the Red and White vaccine.

"Of the 6 candidates for the Red and White Vaccine that was developed, Airlangga's vaccine is at the forefront and the fastest in the development process," he said.

Therefore, Yahya hopes that the phase II preclinical test process and the clinical trial of the Red and White Vaccine made by Unair will run smoothly.

So, he said, in the first half of 2022, BPOM has received an emergency use authorization (EUA) and it can be mass-produced for domestic needs. More than that, Indonesia will be included in the ranks of countries that can make their own vaccines, such as America, Britain, Russia and China," said Yahya.


The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)